Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869373 | 0.94 | SLC29A1 (0.50) | CYP1A2CYP2C19SLC29A1KCNH3KMT2A | |
| SCHEMBL9913723 | 0.94 | SLC29A1 (0.50) | CYP1A2CYP2C19SLC29A1KCNH3KMT2A | |
| SCHEMBL24433634 | 0.92 | LMNA (0.50) | CYP1A2CYP2C19LMNAKCNH3KMT2A | |
| SCHEMBL9913716 | 0.92 | CYP1A2 (0.57) | CYP1A2CYP2C19LMNASLC29A1KCNH3 | |
| SCHEMBL14869524 | 0.88 | KCNH3 (0.56) | CYP1A2CYP2C19SLC29A1KCNH3KMT2A | |
| SCHEMBL17563606 | 0.87 | LMNA (0.54) | CYP1A2CYP2C19LMNAKMT2ACA1 | |
| SCHEMBL14869427 | 0.86 | SLC29A1 (0.45) | LMNASLC29A1KCNH3KMT2ACA1 | |
| SCHEMBL2784348 | 0.86 | KMT2A (0.59) | CYP1A2CYP2C19LMNASLC29A1KCNH3 | |
| SCHEMBL2784426 | 0.85 | SLC29A1 (0.57) | CYP1A2CYP2C19SLC29A1KCNH3KMT2A | |
| SCHEMBL14869406 | 0.85 | LMNA (0.61) | CYP1A2CYP2C19LMNAKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2562864-A1 | Proton-conducting polymer | Nippon Steel Chemical Co., Ltd. (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-8198387-B2 | Proton-conducting compound and proton-conducting polymer | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | NIPPON STREEL CHEMICAL CO., LTD (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | HRH3, H1-3, H1-4 | CYP1A2 2994/4885CYP2C19 704/4885LMNA 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.